BioVex.com

Amgen.com

Testing a new approach in advanced melanoma

OPTiM - Testing a New Approach in Advanced Melanoma. OPTiM is a Phase 3 clinical study evaluating a new investigational agent called OncoVEXGM-CSF.
            
            
            
Image © iStockphoto.com

Clinical trials are scientific research studies designed to find better ways to treat or prevent diseases. Whether you are a patient or a caregiver, our goal for this website is to answer your questions and help you understand the clinical trial experience.

OncoVEXGM-CSF
(talimogene laherparepvec)

OncoVEXGM-CSF is now being tested to see if it can provide an effective treatment for people with melanoma. It is an investigational agent, which means it has not been approved by the Food and Drug Administration (FDA) for marketing.

Testing a new approach in advanced melanoma

© 2011 Amgen Inc. All Rights Reserved | Privacy & Terms